19 August, 2012

ONE MORE DPP IV IN THE MARKET!! SOUNDS PROMISING!


Linagliptin (BI-1356, trade names Tradjenta  and Trajenta (in india)) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.
Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly
Mechanism of action
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output. Thus, linagliptin stimulates the release of insulin in a glucose-dependent manner and decreases the levels of glucagon in the circulation.

with so many gliptins in the market we will have to wait to get reports on the clinical effectiveness of this new molecule.

2 comments :

  1. Where can we find it in chennai.any place in particular.

    ReplyDelete
  2. it is available in all big pharmacies all over chennai

    ReplyDelete

Feel free to Comment!!

ShareThis